Brief: Ligand Pharmaceuticals Entered Third Amendment To Credit Agreement - SEC Filing
16/09/2025 22:31
Sept 16 (Reuters) - SEC Filing: LIGAND PHARMACEUTICALS INC - ON SEPTEMBER 12, CO ENTERED THIRD AMENDMENT TO CREDIT AGREEMENT - SEC FILING LIGAND PHARMACEUTICALS INC - MATURITY DATE EXTENDED TO SEPTEMBER 12, 2028 - SEC FILING Source text: [ID:n0001193125-25-205147] Further company coverage: LGND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan